新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » FDA信息 » FDA授予Telik公司MDS药物Telintra孤儿药地位

FDA授予Telik公司MDS药物Telintra孤儿药地位

来源:生物谷 2013-01-15 00:16

2013年1月14日讯 /生物谷BIOON/ --Telik制药宣布,FDA已授予Telintra(Ezatiostat HCl)孤儿药地位,用于骨髓增生异常综合症(myelodysplastic syndrome,MDS)的治疗。

Telintra是一种新颖的谷胱甘肽S-转移酶P1-1(glutathione S-transferase P1-1,GSTP1-1)抑制剂,能够可逆性抑制GSTP1-1,导致Jun激酶(JNK)的激活,该酶是血液前体细胞生长及分化的关键调节子。(生物谷bioon.com)

英文原文:Palo Alto, CA – January 11, 2013 – Telik, Inc. (Nasdaq: TELK) was notified today that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of myelodysplastic syndrome (MDS).  Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.  Additional potential benefits of orphan designation include development grants, tax credits related to clinical trial expenses, protocol development assistance and exemption from FDA user fees.  The US Orphan Drug Act aims to encourage the development of drugs for the diagnosis, prevention and treatment of medical conditions affecting fewer than 200,000 people in the US.

Telintra is an investigational agent in development for the treatment of MDS and idiopathic chronic neutropenia.  Telintra is a novel inhibitor of the enzyme glutathione S-transferase P1‑1, leading to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells.  Telintra has been shown to cause clinically significant and sustained reduction in red blood cell transfusions, transfusion independence and multilineage responses in MDS patients.  The results of four clinical trials of Telintra in MDS have been reported in peer-reviewed scientific journals.

本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库